Watch-and-wait after immunotherapy for early-stage GI cancers
Part of Cancer, Digestive system clinical trials.
This study looks at whether some patients with early-stage stomach, colon, or rectal cancers that are mismatch repair-deficient (a genetic feature making them more likely to respond to immunotherapy) can safely avoid surgery and instead be monitored closely after treatment with immunotherapy. It aims to confirm if this watch-and-wait approach is as effective and helps patients avoid major operations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with stomach, colon, or rectal cancer that has not spread to other organs (non-metastatic)
- Your tumor shows signs of 'mismatch repair deficiency' (a genetic marker found by a lab test)
- Your cancer was treated with immunotherapy as your first treatment, either as a single drug or a combination of drugs
- If you are in Part B of the study, you must have had a complete or near-complete response to immunotherapy, as determined by your doctors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying people with a specific type of advanced colorectal cancer (MSI-high/dMMR) who are starting immunotherapy with pembrolizumab. The goal is to find out which markers in the tumor might predict whether the treatment works well.
This trial looks at whether people with certain types of colorectal or other gastrointestinal cancers can avoid or delay surgery and instead be monitored closely (watch-and-wait) after receiving immunotherapy. It aims to see if this approach can keep the cancer from coming back while improving quality of life.
This trial looks at whether some patients with gastrointestinal cancers that have specific genetic markers can safely avoid surgery after immunotherapy, or have a less invasive procedure, instead of the standard radical surgery. It aims to see which approach is safer and more effective.
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
Hear when a new Quality of Life (QOL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.